Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -54.83% | 1.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -54.83% | 1.72% | |||
| Cost of Revenue | -14.96% | 12.33% | |||
| Gross Profit | -5.81% | -18.79% | |||
| SG&A Expenses | 9.04% | -11.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.22% | 6.77% | |||
| Operating Income | -6.69% | -8.82% | |||
| Income Before Tax | -9.05% | -3.84% | |||
| Income Tax Expenses | 114.53% | -631.82% | |||
| Earnings from Continuing Operations | -10.47% | -2.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.47% | -2.44% | |||
| EBIT | -6.69% | -8.82% | |||
| EBITDA | -7.21% | -9.48% | |||
| EPS Basic | -10.09% | -1.90% | |||
| Normalized Basic EPS | -8.66% | -10.50% | |||
| EPS Diluted | -10.09% | -1.90% | |||
| Normalized Diluted EPS | -8.66% | -10.50% | |||
| Average Basic Shares Outstanding | 0.34% | 0.52% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||